IRLAB presents at two Redeye events
Gothenburg, Sweden, April 7, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announces that Kristina Torfgård, CEO and Viktor Siewertz, CFO will present the latest from IRLAB’s pipeline at Redeye Theme: Alzheimer’s & Parkinson’s on April 8 and at Redeye Investor Forum in Gothenburg on April 10, respectivly.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >